• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Synteract Expands Into Asia Pacific and South Africa Through Acquisition of Specialty Biometrics CRO

Share:

February 10, 2020

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint into Asia Pacific and Africa, and offers another core biometrics services hub, complementary to those it operates in Europe and the U.S.

Clindata, with offices in Bloemfontein, South Africa, and Colombo, Sri Lanka, is a biometrics Clinical Research Organization, offering biostatistics, programming and data management services across all phases of drug development. Clindata’s Veterinary division will continue to operate under the Clindata name, independently from Synteract, while the Human Health Biometrics division will combine with Synteract. The combination of Clindata’s experienced team of biometrics professionals with that of Synteract’s further enhances Synteract’s biometrics capabilities as part of its integrated, full-service program; dedicated FSP solution, or as a standalone biometrics service to augment clients’ in-house capabilities.

“Like Synteract, Clindata is known for high quality service delivery, collaboration, agility and expertise of its teams,” says Synteract CEO Steve Powell. “Innovative changes in biometrics are transforming the ways in which clinical study data is collected, integrated and analyzed. Rich patient data gives researchers insights into disease progression and response to therapy in ways we have not seen before. This is an exciting time to be adding even more expertise to our teams and will allow us to deliver global biometrics services covering every time-zone.”

With a wealth of data management, CDISC, biostatistics and SAS experience, the Clindata team have significant experience running Phase I-IV studies across the complementary therapeutic areas of Synteract. Clindata CEO, Theo Erasmus, adds, “With our combined biometrics capabilities, clients will benefit from a complete service offering incorporating all data components from research, advice on study design, document planning to PK analyses and results interpretation, as well as global capabilities, all provided by one integrated CRO. We are glad to be joining Synteract and creating a world class delivery team.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Synteract is a portfolio company of Amulet Capital Partners, LP. Financial terms are not being disclosed.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Griffin-American Healthcare REIT IV Completed Acquisitions Totaling More than $200 Million During the Fourth Quarter 2018Griffin-American Healthcare REIT IV Completed Acquisitions Totaling More than $200 Million During the Fourth Quarter 2018
  • How Stakeholders Should Push Digital Health Services to Fight COVID-19How Stakeholders Should Push Digital Health Services to Fight COVID-19
  • Lifepoint Health and Ascension Saint Thomas Announce Joint VentureLifepoint Health and Ascension Saint Thomas Announce Joint Venture
  • Inscopix Announces Collaboration With Bruker for Advanced Analysis of Brain Circuits by Combining Miniature Microscopes With Multiphoton MicroscopyInscopix Announces Collaboration With Bruker for Advanced Analysis of Brain Circuits by Combining Miniature Microscopes With Multiphoton Microscopy
  • The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine CandidateThe University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine Candidate
  • Telehealth Startups Rake in Money During the PandemicTelehealth Startups Rake in Money During the Pandemic
  • Mesoblast gets access to China though deal with TaslyMesoblast gets access to China though deal with Tasly
  • Vuno Signs License Agreement with M3 for Expansion in Japanese MarketVuno Signs License Agreement with M3 for Expansion in Japanese Market

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications